Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025

Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) reported Q3 2025 net revenues of $191.8M, GAAP net income of $17.4M or $0.37 per diluted share, and adjusted non-GAAP net income of $44.7M or $0.93 per diluted share for the three months ended September 30, 2025.

Key drivers included BAQSIMI sales of $53.6M (14% growth year‑over‑year) and the August 2025 launch of iron sucrose injection ($2.4M). GAAP results were affected by a $23.1M litigation provision included in general and administrative expenses and a $5.3M upfront R&D payment under an exclusive license with Nanjing Anji for three proprietary peptides. Operating cash flow for the nine months ended September 30, 2025 was $123.3M. The company will hold a conference call on November 6, 2025 at 2:00 p.m. PT.

Positive

• Net revenues of $191.8M in Q3 2025
• Adjusted non-GAAP net income of $44.7M (Q3 2025)
• BAQSIMI revenue $53.6M, +14% YoY
• Launched iron sucrose injection in Aug 2025 with $2.4M sales
• Operating cash flow of $123.3M for nine months ended Sept 30, 2025

Negative

• GAAP net income declined to $17.4M in Q3 2025 from $40.4M in Q3 2024
• Glucagon revenue fell 49% YoY (down $13.2M)
• General & administrative expenses increased 166% due to a $23.1M litigation provision
• R&D rose partly from a $5.3M upfront licensing payment to Nanjing Anji

Insights

Equity Financial Analyst

Quarter shows stable revenues but weaker GAAP profits; growth driven by BAQSIMI and a new generic launch while litigation and pricing pressure weigh on margins.

Net revenues were essentially flat at $191.8 million versus last year, with product revenues up slightly to $191.8 million. Growth concentrated in BAQSIMI (sales up 14% year-over-year in unit terms) and new iron sucrose injection launched in August 2025 contributing $2.4 million. Offsets included material declines in glucagon (down 49 year-over-year) and pricing pressure on epinephrine multi-dose vials, which reduced revenue and gross margin.

Cost and operating items drove the profit compression. GAAP net income fell to $17.4 million (GAAP EPS $0.37) while adjusted non-GAAP net income was $44.7 million (adjusted EPS $0.93). The company recorded a $23.1 million litigation provision that materially increased G&A and a $5.3 million upfront R&D licensing payment, both affecting near-term profitability; gross margin declined to 51.4% from 53.3%.

Dependencies and risks are clear and measurable: ongoing pricing pressure in certain legacy products, the realization of sales from BAQSIMI marketing expansion, and the financial impact of litigation. Watch upcoming disclosures for litigation resolution, sequential sales trends for BAQSIMI and iron sucrose, and any FDA or commercial milestones tied to the licensed peptides; near-term signals likely within the next 12 months.

• Reports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025

• GAAP net income of $17.4 million, or $0.37 per share, for the third quarter

• Adjusted non-GAAP net income of $44.7 million, or $0.93 per share, for the third quarter

• Company to hold a conference call today at 2:00 p.m. Pacific Time

RANCHO CUCAMONGA, CA / ACCESS Newswire / November 6, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended September 30, 2025.

"Amphastar delivered another strong quarter, led by double-digit growth from BAQSIMI ^®, which achieved a 14% increase in revenue compared to the same period last year. Additionally, we received FDA approval and launched iron sucrose injection, a key generic alternative which expands patient access to affordable therapies while contributing to our revenue growth. This achievement underscores our commitment to advancing complex generics and leveraging our domestic in-house manufacturing expertise to deliver high-quality therapies to patients. In addition, we bolstered our proprietary pipeline through an exclusive licensing agreement with Nanjing Anji Biotechnology to develop and commercialize three novel peptides targeting high-growth markets across oncology and ophthalmology," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "Together, our sustained commercial momentum, strategic pipeline expansion, and recent FDA approval, position Amphastar to accelerate growth and drive long-term value across its portfolio."

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
		(in thousands, except per share data)
Net revenues		$	191,840			$	191,214			$	536,782			$	545,444
GAAP net income		$	17,350			$	40,429			$	73,665			$	121,555
Adjusted non-GAAP net income*		$	44,696			$	49,585			$	122,460			$	153,569
GAAP diluted EPS		$	0.37			$	0.78			$	1.52			$	2.32
Adjusted non-GAAP diluted EPS*		$	0.93			$	0.96			$	2.52			$	2.94

________________________________________

* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.

Third Quarter Results

		Three Months Ended
		September 30,								Change
		2025				2024				Dollars				%
		(in thousands)
Product revenues, net:
BAQSIMI ®		$	53,608			$	40,409			$	13,199				33	%
Primatene MIST ®			28,808				26,055				2,753				11	%
Epinephrine			18,789				21,341				(2,552	)			(12	)%
Glucagon			13,558				26,792				(13,234	)			(49	)%
Lidocaine			12,932				15,884				(2,952	)			(19	)%
Other products			64,145				58,338				5,807				10	%
Total product revenues, net		$	191,840			$	188,819			$	3,021				2	%
Other revenues			-				2,395				(2,395	)			(100	)%
Total net revenues		$	191,840			$	191,214			$	626				0	%

Changes in product revenues, net as compared to the third quarter of the prior year were primarily driven by:

• BAQSIMI ^® sales increased primarily due to an increase in unit volumes, as a result of an expanded marketing effort in the United States; total sales of BAQSIMI ^® grew 14% from the prior year's quarter including prior quarter sales by Eli Lilly and Company, or Lilly, which was accounted for in Other revenues

• Primatene MIST ^® sales increased due to an increase in unit volumes driven by our continued marketing efforts

• Epinephrine sales decreased due to a lower average selling price of the multi-dose vial product, causing a revenue reduction of $3.1 million, as a result of increased competition. This trend was partially offset by an increase in unit volumes for our epinephrine pre-filled syringe, as a result of an increase in demand caused by shortages from other suppliers during the quarter

• Glucagon sales decreased primarily due to a lower average selling price, impacting sales by $7.0 million, as well as a decrease in unit volumes, impacting sales by $6.2 million, as a result of competition and the continued shift to ready to use glucagon products such as BAQSIMI ^®

• Lidocaine sales decreased primarily due to a decrease in unit volumes, as a result of other suppliers returning to their historical distribution levels

• Other pharmaceutical product sales changes were primarily due to an increase in sales of albuterol totaling $4.7 million as well as sales of iron sucrose injection, which we launched in August 2025 totaling $2.4 million. This increase was partially offset by a decrease in unit volumes of enoxaparin and dextrose, primarily due to increased competition

• Other revenues were zero in the third quarter of 2025 as we completed the assumption of distribution responsibilities globally for BAQSIMI ^® at the beginning of 2025, with all of BAQSIMI ^® related revenues in the current period being recognized in Product revenues, net. Other revenues in the previous period consisted of $2.4 million in BAQSIMI ^® sales made by Lilly on our behalf under the Transition Service Agreement, or TSA, and was net of $4.0 million in cost of sales and other expenses

		Three Months Ended
		September 30,								Change
		2025				2024				Dollars				%
		(in thousands)
Net revenues		$	191,840			$	191,214			$	626				0	%
Cost of revenues			93,194				89,273				3,921				4	%
Gross profit		$	98,646			$	101,941			$	(3,295	)			(3	)%
as % of net revenues			51.4	%			53.3	%

Changes in the cost of revenues and gross margin were primarily driven by:

• Decrease in other revenues related to Lilly's sales of BAQSIMI ^® under the TSA, which were recorded net of cost of sales and other expenses; as we assumed distribution of BAQSIMI ^® to all of our customers by the beginning of 2025, we recorded those sales in product revenues and cost of sales separately

• Decrease in unit sales and pricing of glucagon, and lower pricing for our epinephrine multi-dose vial product, both of which are higher-margin products

• Cost control efforts across the business partially offset the impact of pricing declines

		Three Months Ended
		September 30,								Change
		2025				2024				Dollars				%
		(in thousands)
Selling, distribution, and marketing		$	11,505			$	8,995			$	2,510				28	%
General and administrative			39,467				14,821				24,646				166	%
Research and development			22,354				21,077				1,277				6	%

• Selling, distribution, and marketing expenses increased primarily due to the expansion of our sales and marketing efforts related to BAQSIMI ^® , including expenses related to our co-promotion contract with MannKind, and sales efforts related to Primatene MIST ^®

• General and administrative expenses increased primarily due to a litigation provision, which increased expenses by $23.1 million

• Research and development expenses increased primarily due to the $5.3 million upfront payment for the licensing agreement that we entered into with Nanjing Anji Biotechnology Co., Ltd. ("Anji"), during the quarter, as well as an increase in clinical trial expense. This was partially offset by a decrease in materials and supply expenses

		Three Months Ended
		September 30,								Change
		2025				2024				Dollars				%
		(in thousands)
Non-operating expenses:
Interest income		$	2,246			$	2,427			$	(181	)			(7	)%
Interest expense			(6,284	)			(6,698	)			414				(6	)%
Other income (expenses), net			231				(5,094	)			5,325				105	%
Total non-operating expenses, net		$	(3,807	)		$	(9,365	)		$	5,558				(59	)%

The change in non-operating expenses, net is primarily due to a change in Other income (expenses), net, as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the three months ended September 30, 2025.

Cash flow provided by operating activities for the nine months ended September 30, 2025, was $123.3 million.

Pipeline Information

The Company currently has three abbreviated new drug applications ("ANDAs") and one biosimilar insulin candidate filed with the FDA targeting products with a combined market size exceeding $2 billion, along with three biosimilar products in development targeting products with a market size exceeding $6 billion, and two generic products in development targeting products with a market size of over $1 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2025. The Company is developing multiple proprietary products with injectable and intranasal dosage forms.

The Company entered into an exclusive license agreement with Anji for the development, manufacturing, use, and commercialization of three proprietary peptides. The first product is based on the discovery by Anji of an endogenous peptide that demonstrates a novel mechanism of action that potentially suppresses the growth and metastasis of multiple poorly treated cancers. The second product is a novel peptide-docetaxel conjugate that targets a specific receptor, designed to improve the selectivity and bioavailability of docetaxel. It is designed to reduce docetaxel-induced toxicity, which will improve the efficacy and safety of current taxane therapies. The third product is an anti-vascular endothelial growth factor receptor (VEGFR) peptide of novel design, developed as a topical eye drop for the treatment of wet age-related macular degeneration (wAMD). It is intended to be an alternative to the routine eye injections used for current treatment.

Conference Call Information

The Company will hold a conference call to discuss its financial results today, November 6, 2025, at 2:00 p.m. Pacific Time.

To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.

The call can also be accessed on the Investors page on the Company's website at www.amphastar.com.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally excludes amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI ^® , certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Market Data

This press release contains market data that we obtained from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other projections. While we believe these assumptions to be reasonable and sound as of the date of this press release, actual results may differ from the projections.

About Amphastar Pharmaceuticals, Inc.

Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ^®, BAQSIMI ^®, Primatene MIST ^®, REXTOVY ^®, Amphadase ^®, and Cortrosyn ^®, are the property of Amphastar.

Forward-Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our manufacturing in-house expertise, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI ^®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact Information:

Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416

Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
Net revenues:
Product revenues, net		$	191,840			$	188,819			$	536,782			$	525,836
Other revenues			-				2,395				-				19,608
Total net revenues			191,840				191,214				536,782				545,444
Cost of revenues			93,194				89,273				266,395				258,237
Gross profit			98,646				101,941				270,387				287,207
Operating expenses:
Selling, distribution, and marketing			11,505				8,995				33,606				27,378
General and administrative			39,467				14,821				69,454				43,782
Research and development			22,354				21,077				62,530				55,772
Total operating expenses			73,326				44,893				165,590				126,932
Income from operations			25,320				57,048				104,797				160,275
Non-operating expenses:
Interest income			2,246				2,427				6,256				8,320
Interest expense			(6,284	)			(6,698	)			(18,851	)			(23,918	)
Other income (expenses), net			231				(5,094	)			(492	)			1,125
Total non-operating expenses, net			(3,807	)			(9,365	)			(13,087	)			(14,473	)
Income before income taxes			21,513				47,683				91,710				145,802
Income tax provision			4,163				7,254				18,045				23,674
Income before equity in losses of unconsolidated affiliate			17,350				40,429				73,665				122,128
Equity in losses of unconsolidated affiliate			-				-				-				(573	)
Net income		$	17,350			$	40,429			$	73,665			$	121,555
Net income per share:
Basic		$	0.38			$	0.83			$	1.57			$	2.50
Diluted		$	0.37			$	0.78			$	1.52			$	2.32
Weighted-average shares used to compute net income per share:
Basic			46,474				48,621				47,021				48,580
Diluted			47,677				51,862				48,565				52,307

Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; in thousands, except share data)

		September 30,				December 31,
		2025				2024
		(unaudited)
ASSETS
Current assets:
Cash and cash equivalents		$	216,265			$	151,609
Restricted cash			235				235
Short-term investments			59,944				70,036
Restricted short-term investments			2,200				2,200
Accounts receivable, net			146,808				136,289
Inventories, net			185,932				153,741
Income tax refunds and deposits			2,065				1,747
Prepaid expenses and other assets			26,021				18,214
Total current assets			639,470				534,071
Property, plant, and equipment, net			308,689				297,345
Finance lease right-of-use assets			259				383
Operating lease right-of-use assets			44,577				46,899
Goodwill and intangible assets, net			572,237				590,660
Long-term investments			-				10,996
Other assets			29,866				25,992
Deferred tax assets			71,124				71,124
Total assets		$	1,666,222			$	1,577,470
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$	190,844			$	157,057
Income taxes payable			5,633				9,664
Current portion of long-term debt			923				234
Current portion of operating lease liabilities			7,827				6,804
Total current liabilities			205,227				173,759
Long-term reserve for income tax liabilities			6,957				6,957
Long-term debt, net of current portion and unamortized debt issuance costs			608,582				601,630
Long-term operating lease liabilities, net of current portion			39,441				41,881
Other long-term liabilities			29,269				20,945
Total liabilities			889,476				845,172
Commitments and contingencies
Stockholders' equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding			-				-
Common stock: par value $0.0001; 300,000,000 shares authorized; 61,677,781 and 46,348,863 shares issued and outstanding, respectively, as of September 30, 2025 and 60,847,124 and 47,617,691 shares issued and outstanding, respectively, as of December 31, 2024			6				6
Additional paid-in capital			527,215				505,400
Retained earnings			642,451				568,787
Accumulated other comprehensive loss			(5,273	)			(9,181	)
Treasury stock			(387,653	)			(332,714	)
Total stockholders' equity			776,746				732,298
Total liabilities and stockholders' equity		$	1,666,222			$	1,577,470

Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)

		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2025			2024			2025			2024
GAAP net income		$	17,350		$	40,429		$	73,665		$	121,555
Adjusted for:
Intangible asset amortization			6,269			6,179			18,778			18,539
Share-based compensation			6,297			5,596			21,072			18,736
Expenses related to BAQSIMI ® acquisition			-			-			-			3,651
Litigation provision			23,147			-			23,147			-
Income tax provision on pre-tax adjustments			(8,367)			(2,619)			(14,202)			(8,912)
Adjusted non-GAAP net income		$	44,696		$	49,585		$	122,460		$	153,569
Adjusted non-GAAP net income per share:
Basic		$	0.96		$	1.02		$	2.60		$	3.16
Diluted		$	0.93		$	0.96		$	2.52		$	2.94
Weighted-average shares used to compute adjusted non-GAAP net income per share:
Basic			46,474			48,621			47,021			48,580
Diluted			47,677			51,862			48,565			52,307

		Three Months Ended September 30, 2025
						Selling,				General				Research				Non-operating
		Cost of				distribution				and				and				(expenses)				Income
		revenue				and marketing				administrative				development				income, net				tax provision
GAAP		$	93,194			$	11,505			$	39,467			$	22,354			$	(3,807	)		$	4,163
Intangible asset amortization			(6,248	)			-				(1	)			(20	)			-				-
Share-based compensation			(1,274	)			(301	)			(4,140	)			(582	)			-				-
Litigation provision			-				-				(23,147	)			-				-				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				8,367
Non-GAAP		$	85,672			$	11,204			$	12,179			$	21,752			$	(3,807	)		$	12,530

		Three Months Ended September 30, 2024
						Selling,				General				Research				Non-operating
		Cost of				distribution				and				and				(expenses)				Income
		revenue				and marketing				administrative				development				income, net				tax provision
GAAP		$	89,273			$	8,995			$	14,821			$	21,077			$	(9,365	)		$	7,254
Intangible asset amortization			(6,159	)			-				(1	)			(19	)			-				-
Share-based compensation			(1,133	)			(249	)			(3,710	)			(504	)			-				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				2,619
Non-GAAP		$	81,981			$	8,746			$	11,110			$	20,554			$	(9,365	)		$	9,873

		Nine Months Ended September 30, 2025
						Selling,				General				Research				Non-operating
		Cost of				distribution				and				and				(expenses)				Income
		revenue				and marketing				administrative				development				income, net				tax provision
GAAP		$	266,395			$	33,606			$	69,454			$	62,530			$	(13,087	)		$	18,045
Intangible asset amortization			(18,718	)			-				(2	)			(58	)			-				-
Share-based compensation			(5,012	)			(925	)			(12,777	)			(2,358	)			-				-
Litigation provision			-				-				(23,147	)			-				-				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				14,202
Non-GAAP		$	242,665			$	32,681			$	33,528			$	60,114			$	(13,087	)		$	32,247

		Nine Months Ended September 30, 2024
						Selling,				General				Research				Non-operating
		Cost of				distribution				and				and				(expenses)				Income
		revenue				and marketing				administrative				development				income, net				tax provision
GAAP		$	258,237			$	27,378			$	43,782			$	55,772			$	(14,473	)		$	23,674
Intangible asset amortization			(18,479	)			-				(4	)			(56	)			-				-
Share-based compensation			(4,583	)			(777	)			(11,239	)			(2,137	)			-				-
Expenses related to BAQSIMI ® acquisition			-				-				-				-				3,651				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				8,912
Non-GAAP		$	235,175			$	26,601			$	32,539			$	53,579			$	(10,822	)		$	32,586

SOURCE: Amphastar Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

What were Amphastar (AMPH) Q3 2025 revenues and EPS on November 6, 2025?

Amphastar reported Q3 2025 net revenues $191.8M, GAAP diluted EPS $0.37, and adjusted non-GAAP diluted EPS $0.93.

How did BAQSIMI perform for Amphastar in Q3 2025 (AMPH)?

BAQSIMI generated $53.6M in Q3 2025 revenue, a 14% increase year‑over‑year driven by higher unit volumes.

What caused Amphastar's higher G&A expense in Q3 2025 (AMPH)?

G&A rose primarily due to a $23.1M litigation provision recorded in the quarter.

When is Amphastar's Q3 2025 earnings call and how can investors join (AMPH)?

The company held its conference call on November 6, 2025 at 2:00 p.m. PT; access was via the investor relations page or the provided dial‑in numbers.

Did Amphastar launch any new products in 2025 that affected revenue (AMPH)?

Yes; Amphastar launched iron sucrose injection in August 2025, recording $2.4M in sales in Q3 2025.

What pipeline or licensing news did Amphastar disclose on November 6, 2025 (AMPH)?

Amphastar signed an exclusive license with Nanjing Anji to develop and commercialize three proprietary peptides, paying a $5.3M upfront fee.